OPK:NGS-Opko Health Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 1.26

Change

0.00 (0.00)%

Market Cap

USD 5.69B

Volume

1.95M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

OPKO Health Inc is a diversified healthcare company. The Company's operating business segments are diagnostics and pharmaceutical.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 41.47B
ICLR ICON PLC

N/A

USD 25.49B
ILMN Illumina Inc

N/A

USD 19.47B
MEDP Medpace Holdings Inc

N/A

USD 12.27B
NTRA Natera Inc

N/A

USD 11.20B
EXAS EXACT Sciences Corporation

N/A

USD 10.68B
RDNT RadNet Inc

N/A

USD 3.57B
SHC Sotera Health Co

N/A

USD 3.10B
OLK Olink Holding AB ADR

N/A

USD 2.72B
NEOG Neogen Corporation

N/A

USD 2.63B

ETFs Containing OPK

IPOL:LSE iShares V Public Limited .. 18.22 % 0.00 %

N/A

USD 0.16B
SPOL:LSE iShares MSCI Poland UCITS 18.22 % 0.00 %

N/A

USD 0.16B
IBCJ:F iShares V Public Limited .. 18.22 % 0.00 %

N/A

USD 0.16B
IBCJ:XETRA iShares MSCI Poland UCITS 18.22 % 0.00 %

N/A

USD 0.16B
EPOL iShares MSCI Poland ETF 14.32 % 0.63 %

N/A

USD 0.34B
HVAX:CA 5.26 % 0.00 %

N/A

N/A
EMDM First Trust Bloomberg Eme.. 3.00 % 0.00 %

N/A

USD 5.65M
EXSD:F iShares STOXX Europe Mid .. 0.91 % 0.00 %

N/A

USD 0.47B
EXSD:XETRA iShares STOXX Europe Mid .. 0.91 % 0.00 %

N/A

USD 0.45B
QRH:CA 0.00 % 1.20 %

N/A

N/A
VIDI Vident International Equi.. 0.00 % 0.63 %

N/A

USD 0.37B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.56% 48% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.56% 48% F 29% F
Trailing 12 Months  
Capital Gain -14.29% 63% D 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.29% 63% D 37% F
Trailing 5 Years  
Capital Gain -47.93% 50% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.93% 50% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 16.28% 66% D+ 76% C+
Dividend Return 16.28% 66% D+ 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 82.06% 36% F 19% F
Risk Adjusted Return 19.84% 70% C- 57% F
Market Capitalization 5.69B 69% C- 71% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.12 48% 34%
Price/Book Ratio 0.62 77% 86%
Price / Cash Flow Ratio -31.15 92% 91%
Price/Free Cash Flow Ratio -16.61 87% 88%
Management Effectiveness  
Return on Equity -12.80% 75% 48%
Return on Invested Capital -9.40% 75% 40%
Return on Assets -4.73% 73% 41%
Debt to Equity Ratio 15.98% 74% 65%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector